NPPA fixes retail prices for six formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for six formulations under the Drugs (Prices Control) Order, 2013, based on the decision of the authority meeting held on 29th July, 2021.

In its recent order, the authority said that it has fixed the retail prices for Budesonide Respule by Softdeal Pharmaceutical, Paracetamol plus Caffeine tablet by Micro Labs, two strengths of Metoprolol Succinate (extended release) plus Clinidipine plus Telmisartan tablet by Pure & Cure Healthcare and Alembic Pharmceuticals, Atorvastatin plus Ezetimibe tablet by Safetab Life Sciences and Lupin, and Cefixime plus Potassium Clavulanate tablet by Zeneka Healthcare and Cadila Pharmaceuticals.

The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price mentioned by the NPPA. The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail prices specified by the NPPA in the order.

It also said,” The manufacturer shall issue a price list in Form V from the date of notification as per the DPCO 2013 to NPPA through the integrated pharmaceutical database management system and submit a copy to the state drug controller and dealers. Every retailer and dealer shall display price list and supplementary price list, if any, as furnished by the manufacturer on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.”

In case, the retail price is not complied with, the concerned manufacturer or marketing company shall be liable to deposit the overcharged amount along with the interest under the provisions of the DPCO 2013, read with the Essential Commodities Act, 1955, mentioned the order.